Shionogi Inc - Company Profile
Powered by 
All the sales intelligence you need on Shionogi Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Shionogi Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Shionogi Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Shionogi Inc (Shionogi), a subsidiary of Shionogi & Co Ltd, is a pharmaceutical company that develops and commercializes pharmaceutical products to address unmet medical needs. The company offers a wide range of branded prescription products to treat chronic diseases. It markets products for various therapeutic areas such as pain, anti-infectives, women's health, pediatrics, cardiovascular, and others. Shionogi offers its products in various formulations such as tablets, oral suspensions (solutions), lotions, chewable tablets, capsules, and injections. Some of the company’s key branded products include Fortamet, and Methylin, among others. Shionogi is headquartered in Florham Park, New Jersey, the US.
Headquarters
United States of America
Address
400 Campus Drive, Florham Park, New Jersey, 07932
Website
www.shionogi.com/us/en/
Telephone
1 973 9666900
Industry
Pharmaceuticals and Healthcare
Revenue (2025)
$153.5M
Shionogi Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Cardiovascular | Mulpleta |
| Gastroenterology | Methylin |
| Diabetes | Fetroja |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In December, the company acquired Akros Pharma from Japan Tobacco Inc. |
| 2024 | Regulatory Approval | In October, the company received fast track designation from the US FDA for the novel anti-respiratory syncytial virus drug candidate s-337395. |
| 2023 | Contracts/Agreements | In October, the company as a new joint venture secured a contract with Apnimed, Inc. to develop novel pharmacologic therapies to treat obstructive sleep apnea and other sleep disorders. |
Competitor Comparison
| Key Parameters | Shionogi Inc | SciClone Pharmaceuticals Holdings Ltd | Ardelyx Inc | Sigilon Therapeutics Inc | EpiVax Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | China | United States of America | United States of America | United States of America |
| City | Florham Park | Shanghai | Waltham | Cambridge | Providence |
| State/Province | New Jersey | Shanghai | Massachusetts | Massachusetts | Rhode Island |
| No. of Employees | - | 1,050 | 489 | 62 | - |
| Entity Type | Private | Private | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Nathan McCutcheon | Chief Executive Officer; President | Senior Management | 2022 | - |
| Masahiro Fujita | Senior Vice President; Chief Financial Officer | Senior Management | 2022 | - |
| Margaret Borys | Chief Commercial Officer; Executive Vice President | Senior Management | 2024 | - |
| David Benadon | Chief Human Resources Officer; Senior Vice President | Senior Management | 2024 | - |
| Tadashi Hara | Executive Vice President; Chief Operations Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer